High blood pressure, or hypertension, happens when the force of blood in the arteries stays high over time. It can lead to ...

The Dermatology Devices market is expected to grow at a compound annual growth rate (CAGR) of 6.5% over the forecast period, ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Inference-based guidance supports using systemic psoriasis treatments in cancer patients on immune checkpoint inhibitors ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

This was duly noted by Dr. Karen. Arriving at her salon, situated in her house in leafy Stoke Newington—two very sweet pugs ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...